-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-508260-30-01
5
2024-07-30
Patients with poor prognostic OVARian cancers based on the tumor prima
-
2024-515788-73-00
4
2024-07-30
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IM
-
2024-514107-34-00
4
2024-07-18
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)
-
2023-505660-11-00
5
2024-04-24
Cholangiocarcinoma (LTT, 26.0)
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2024-514101-65-00
4
2023-12-21
Multiple Myeloma
-
2024-513811-29-00
5
2023-07-03
Cardiogenic Shock
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-515344-23-00
4
2021-06-17
local advenced pancreatic adenocarcinoma
-
2024-516181-11-00
4
2021-06-10
RELAPSE/REFRACTORY B-CELL LYMPHOMA.
-
2024-511904-18-00
10
2020-07-08
Pancreatic adenocarcinoma (PAC)
-
2024-514362-39-00
4
2019-12-05
Diabetic macular oedema
-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2024-514032-25-00
4
2024-12-11
Patients with a histilogically confirmed diagnosis of cervical squamou